Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Single Arm, Interventional Study to Explore the Efficacy and Safety of Paliperidone ER in the Management of Patients With Acute Agitation and/or Aggression.

Next Previous
Trial Profile

Open-label, Single Arm, Interventional Study to Explore the Efficacy and Safety of Paliperidone ER in the Management of Patients With Acute Agitation and/or Aggression.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary) ; Benzodiazepines; Lorazepam
  • Indications Aggression; Agitation; Psychotic disorders
  • Focus Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Janssen-Cilag

Most Recent Events

  • 20 Dec 2012 Actual initiation date changed from 1 Jan 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov record.
  • 19 Mar 2012 Actual patient number (56) added as reported by ClinicalTrials.gov.
  • 19 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top